CAL
TEVA icon

Capital Analysts LLC’s Teva Pharmaceuticals TEVA Stock Holding History

Capital Analysts LLC’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$210K Hold
6,203
– – ﹤0.01% 685
2026
Q1 		$187K Hold
6,203
– – ﹤0.01% 655
2025
Q4 		$194K Hold
6,203
– – 0.01% 626
2025
Q3 		$125K Hold
6,203
– – ﹤0.01% 681
2025
Q2 		$104K Buy
6,203
+1,061
+21% +$17.1K ﹤0.01% 660
2025
Q1 		$79K Buy
5,142
+526
+11% +$9.4K ﹤0.01% 694
2024
Q4 		$102K Buy
+4,616
New +$84K ﹤0.01% 610
2024
Q2 		– Sell
-196
Closed -$3K – 1236
2024
Q1 		$3K Hold
196
– – ﹤0.01% 1035
2023
Q4 		$2K Hold
196
– – ﹤0.01% 1036
2023
Q3 		$2K Hold
196
– – ﹤0.01% 1064
2023
Q2 		$1K Hold
196
– – ﹤0.01% 992
2023
Q1 		$2K Hold
196
– – ﹤0.01% 929
2022
Q4 		$2K Hold
196
– – ﹤0.01% 1006
2022
Q3 		$2K Hold
196
– – ﹤0.01% 1020
2022
Q2 		$1K Hold
196
– – ﹤0.01% 998
2022
Q1 		$2K Hold
196
– – ﹤0.01% 883
2021
Q4 		$2K Hold
196
– – ﹤0.01% 960
2021
Q3 		$2K Hold
196
– – ﹤0.01% 936
2021
Q2 		$2K Sell
196
-103
-34% -$1.09K ﹤0.01% 893
2021
Q1 		$3K Buy
+299
New +$3.43K ﹤0.01% 936
2017
Q3 		– Sell
-2,120
Closed -$70.4K – 464
2017
Q2 		$70.4K Hold
2,120
– – 0.01% 277
2017
Q1 		$68K Sell
2,120
-50
-2% -$1.71K 0.01% 241
2016
Q4 		$79K Buy
2,170
+550
+34% +$22K 0.01% 236
2016
Q3 		$74.5K Buy
1,620
+115
+8% +$6K 0.01% 229
2016
Q2 		$75.6K Buy
1,505
+280
+23% +$14.9K 0.02% 228
2016
Q1 		$65.5K Buy
1,225
+100
+9% +$5.87K 0.01% 250
2015
Q4 		$73.8K Buy
1,125
+65
+6% +$4.02K 0.02% 243
2015
Q3 		$59.8K Buy
1,060
+350
+49% +$22.7K 0.01% 267
2015
Q2 		$42K Buy
710
+50
+8% +$3.08K 0.01% 297
2015
Q1 		$41.1K Buy
660
+65
+11% +$3.78K 0.01% 301
2014
Q4 		$34.2K Buy
595
+245
+70% +$13.7K 0.01% 294
2014
Q3 		$18.8K Hold
350
– – ﹤0.01% 317
2014
Q2 		$18.3K Hold
350
– – ﹤0.01% 314
2014
Q1 		$18.5K Buy
350
+150
+75% +$6.93K ﹤0.01% 285
2013
Q4 		$8.02K Buy
+200
New +$7.88K ﹤0.01% 298

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Capital Analysts LLC's TEVA Position: Q2 2026 in Review

Capital Analysts LLC held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 6,203 shares worth $210K. The position accounts for ﹤0.01% of the portfolio, ranked #685.

Capital Analysts LLC first reported a position in TEVA in Q4 2013 and has held it in 35 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Capital Analysts LLC held 6,203 shares of Teva Pharmaceuticals worth $210K as of Q2 2026.
  • Capital Analysts LLC left its Teva Pharmaceuticals share count unchanged in Q2 2026.
  • Teva Pharmaceuticals made up ﹤0.01% of Capital Analysts LLC's portfolio in Q2 2026, its #685 holding.
  • Capital Analysts LLC first reported a position in Teva Pharmaceuticals in Q4 2013 and has held it in 35 quarters since.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Capital Analysts LLC's 13F filing for Q2 2026, filed 5 Aug 2026.